Scios edges up after positive panel

SCIO was up $0.65 to $25.21 on Tuesday after the FDA's Cardiovascular and Renal Drugs Advisory Committee last Friday voted 10-0 in favor of approval of SCIO's Natrecor nesiritide recombinant b-type na...